Genmab A/S GNMSF:OTCPK

RT Quote | Exchange | USD
Last | 03/05/21 EST
323.95quote price arrow up+24.87 (+8.32%)
Volume
415
52 week range
159.45 - 456.83

...

Loading . . .

KEY STATS

  • Open319.04
  • Day High323.95
  • Day Low305.90
  • Prev Close299.08
  • 52 Week High456.83
  • 52 Week High Date01/15/21
  • 52 Week Low159.45
  • 52 Week Low Date03/18/20
  • Market Cap19,974.83M
  • Shares Out65.41M
  • 10 Day Average Volume1,752.91
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change36.29

RATIOS/PROFITABILITY

  • EPS (TTM)11.99
  • P/E (TTM)27.03
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Genmab A/S News

There is no recent news for this security.

Latest GNMSF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment...
Deirdre Connelly
Chairman
Jan van de Winkel Ph.D.
Chief Executive Officer
Anthony Mancini
Chief Operating Officer
Anthony Pagano
Chief Financial Officer
Judith Klimovsky M.D.
Executive Vice President
Address
Kalvebod Brygge 43
Koebenhavn V
1560
Denmark